Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 310 matching trials from the live ClinicalTrials.gov search.
Conditions
Immunizations, Vaccination, Influenza, School Health
Interventions
School based flu vaccine: Low intensity, School based flu vaccine: High intensity
Behavioral
Lead sponsor
Monroe County Department of Public Health
Other
Eligibility
4 Years to 13 Years
Enrollment
25,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Conditions
Avian Influenza
Interventions
aH5N1c, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more
Conditions
Influenza, Healthy Volunteers
Interventions
Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
16
States / cities
Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

NCT01657929
Conditions
Influenza A Subtype H5N1 Infection
Interventions
H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 49 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

NCT04565353
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
74,811 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Danville, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Rochester, New York
Conditions
Influenza
Interventions
Quadrivalent VLP Vaccine, Comparator TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more
Conditions
Influenza
Interventions
Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 31 more
Conditions
SARS-CoV-2, Influenza
Interventions
mRNA-1073, mRNA-1010, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
14
States / cities
Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
Completed Not applicable Interventional

Vaccination Uptake (VAX) in PD

NCT02874274
Conditions
Parkinson's Disease
Interventions
Standard of Care, Home Visit Program (HVP)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

NCT00958126
Conditions
Influenza
Interventions
CSL425, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
1,313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 8 more
Conditions
HIV Infections, H1N1 Influenza Virus
Interventions
Influenza A (H1N1) monovalent vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 22 more
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Conditions
Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
28 Days and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Completed Not applicable Interventional

Rule-Based High-Risk Flu

NCT07798882
Conditions
Influenza, Vaccination, Risk Reduction, Health Behavior, Health Promotion
Interventions
Risk reduction
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
51,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Danville, Pennsylvania
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Conditions
Human Influenza
Interventions
Recombinant Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
254,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland, California
Completed No phase listed Observational Accepts healthy volunteers Results available

Immune Responses to the Flu Shot During Pregnancy

NCT02148874
Conditions
Pregnancy
Interventions
influenza virus vaccination
Biological
Lead sponsor
Lisa Christian
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Influenza
Interventions
CSL's 2009 H1N1 Influenza Vaccine (CSL425), Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 9 Years
Enrollment
473 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
13
States / cities
Chandler, Arizona • Melbourne, Florida • Bardstown, Kentucky + 10 more
Conditions
Influenza, Influenza Immunization
Interventions
Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
20
States / cities
Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more